Literature DB >> 21871296

Prognostic value of chromosomal imbalances in squamous cell carcinoma and adenocarcinoma of the lung.

Bernhard C Danner1, Timo Hellms, Klaus Jung, Bastian Gunawan, Vassilios Didilis, Laszlo Füzesi, Friedrich A Schöndube.   

Abstract

BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the most aggressive tumors, with a very low overall survival rate. We investigated surgically resected squamous cell carcinoma (SCC) and adenocarcinoma (AC) to identify chromosomal imbalances and their value for individual prognostication.
METHODS: A total of 80 cases, including 55 SCC and 25 AC, were retrospectively analyzed by comparative genomic hybridization. To model the sequential cytogenetic events, an oncogenetic tree model was applied based on maximum likelihood estimation. Clinicopathologic data and follow-up data were correlated with chromosomal imbalances.
RESULTS: Fifty-one percent of patients were in stage I, 32% in stage II, and 17% in stage III, without statistically significant differences in staging distribution between SCC and AC. The average number of copy number imbalances was higher in SCC than in AC (9.4±1.2 vs 5.4±1.1; p=0.11). Frequency of chromosomal imbalances at -3p, +3q, -4q, +5q, -5q, +7q, and -13q were significantly different between SCC and AC. Subsequently, oncogenetic tree modeling identified different clusters of chromosomal imbalances for SCC and AC. Appearance of the -3p-cluster in SCC was associated with decreased overall survival independent of clinicopathologic parameters (mean, 42.8±7.5 months vs 80.1±9.1 months, log rank p=0.019), whereas in AC no prognostic value could be identified for specific clusters of chromosomal imbalances.
CONCLUSIONS: Although, the limited number of analyzed cases allows a cautious statement on chromosomal imbalances, the oncogenetic tree modeling suggests distinct patterns of cytogenetic evolution for SCC and AC with implications for clinical outcome in SCC.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871296     DOI: 10.1016/j.athoracsur.2011.04.052

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.

Authors:  Anna E Barón; Severine Kako; William J Feser; Heather Malinowski; Daniel Merrick; Kavita Garg; Stephen Malkoski; Shannon Pretzel; Jill M Siegfried; Wilbur A Franklin; York Miller; Holly J Wolf; Marileila Varella-Garcia
Journal:  J Thorac Oncol       Date:  2017-06-19       Impact factor: 15.609

2.  The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma.

Authors:  Lucy F Stead; Stefano Berri; Henry M Wood; Philip Egan; Caroline Conway; Catherine Daly; Kostas Papagiannopoulos; Pamela Rabbitts
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

3.  Loss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer.

Authors:  Faik G Uzunoglu; Ebba Dethlefsen; Annkathrin Hanssen; Michaela Wrage; Lena Deutsch; Katharina Harms-Effenberger; Yogesh K Vashist; Matthias Reeh; Guido Sauter; Ronald Simon; Maximillian Bockhorn; Klaus Pantel; Jakob R Izbicki; Harriet Wikman
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

4.  Cystatin A suppresses tumor cell growth through inhibiting epithelial to mesenchymal transition in human lung cancer.

Authors:  Yunxia Ma; Yuan Chen; Yong Li; Katja Grün; Alexander Berndt; Zhongwei Zhou; Iver Petersen
Journal:  Oncotarget       Date:  2017-12-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.